IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."
IGC Pharma (NYSE American:IGC) announced that Ascendiant Capital Markets has released a new coverage report on the company. The report raises the price target to $4.50 and suggests that upcoming clinical data and progress in 2025 could serve as strong catalysts for the stock.
The company explicitly stated that analyst views represent their independent opinions and that IGC Pharma is not responsible for the content, accuracy, or timelines provided in such reports.
IGC Pharma (NYSE American:IGC) ha comunicato che Ascendiant Capital Markets ha pubblicato una nuova relazione sull’azienda. Il report aumenta il target price a $4.50 e indica che i dati clinici imminenti e i progressi previsti per il 2025 potrebbero rappresentare potenti catalizzatori per il titolo.
La società ha precisato che le opinioni degli analisti riflettono valutazioni indipendenti e che IGC Pharma non è responsabile del contenuto, dell’accuratezza o delle tempistiche riportate in tali report.
IGC Pharma (NYSE American:IGC) anunció que Ascendiant Capital Markets ha publicado un nuevo informe sobre la compañía. El informe eleva el precio objetivo a $4.50 y apunta a que los datos clínicos próximos y los avances previstos en 2025 podrían actuar como catalizadores importantes para la acción.
La compañía precisó que las opiniones de los analistas representan criterios independientes y que IGC Pharma no se hace responsable del contenido, la exactitud ni los plazos señalados en dichos informes.
IGC Pharma (NYSE American:IGC)는 Ascendiant Capital Markets가 회사에 대한 신규 커버리지 보고서를 발행했다고 발표했습니다. 해당 보고서는 목표주가를 $4.50로 상향 조정했으며, 다가오는 임상 데이터와 2025년의 진전이 주가에 강력한 촉매제가 될 수 있다고 분석합니다.
회사는 애널리스트의 견해가 독립적인 의견임을 명확히 했으며, IGC Pharma는 해당 보고서에 기재된 내용, 정확성 또는 일정에 대해 책임을 지지 않는다고 밝혔습니다.
IGC Pharma (NYSE American:IGC) a annoncé qu’Ascendiant Capital Markets a publié un nouveau rapport de couverture sur la société. Le rapport relève l’objectif de cours à 4,50 $ et indique que les données cliniques à venir et les progrès prévus en 2025 pourraient constituer de forts catalyseurs pour l’action.
La société a précisé que les opinions des analystes reflètent leurs avis indépendants et qu’IGC Pharma n’est pas responsable du contenu, de l’exactitude ni des échéances mentionnés dans ces rapports.
IGC Pharma (NYSE American:IGC) gab bekannt, dass Ascendiant Capital Markets einen neuen Coverage-Report über das Unternehmen veröffentlicht hat. Der Bericht hebt das Kursziel auf $4.50 an und stellt fest, dass bevorstehende klinische Daten und Fortschritte im Jahr 2025 starke Katalysatoren für die Aktie sein könnten.
Das Unternehmen stellte klar, dass die Ansichten der Analysten deren unabhängige Meinungen widerspiegeln und IGC Pharma nicht für den Inhalt, die Genauigkeit oder die Zeitangaben in solchen Berichten verantwortlich ist.
- None.
- None.
POTOMAC, MD / ACCESS Newswire / August 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.
A copy of the updated report can be obtained directly from Ascendiant Capital Markets: LINK
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new price target for IGC Pharma (IGC) according to Ascendiant Capital Markets?
What catalysts does Ascendiant Capital Markets identify for IGC stock in 2025?
Does IGC Pharma endorse the analysts' views in the Ascendiant Capital Markets report?
How can investors access the new IGC Pharma coverage report by Ascendiant Capital Markets?
